🔹 Calcitriol in IgA Nephropathy. 🔹 Finerenone Pooled Outcomes (FINE-HEART analysis). 🔹 Real-World Risk of Kidney Failure vs. Death in Diabetes. #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/EPO_Wf_nz2w

In this episode of Podocyte Talk, we delve into three important studies shaping the management of advanced chronic kidney disease (CKD): 🔹 Exercise Before Dialysis 🔹 Cost-Effectiveness of Low-Protein Diets 🔹 Spironolactone in CKD #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/NFMi6Ysez5w

In Episode 29 of Podocyte Talk, we cover three high-impact studies: Measured GFR After Bariatric Surgery Pregnancy and Long-Term Kidney Function in Chronic Kidney Disease Dapagliflozin and Health-Related Quality of Life #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/yUfhuKXL_-s

In Episode 28 of Podocyte Talk, we discuss three clinically relevant studies advancing care in nephrology and transplant medicine: Intradialytic Exercise Trial . EVEREST Post-Hoc Analysis. Transplant Infection Study (India). #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/LEh0boi4Ovc

🎙️New #PodocyteTalk! GLP-1 RAs reduce death & boost transplant listing in dialysis. Biomarkers predict CKD outcomes. Sotradecol foam shrinks cysts in ADPKD/ADPLD. 📺 Watch & subscribe—85% of viewers still haven’t! 🔗 youtu.be/GKCeZsl1s2M #nephrology #CKD

🎙️ In Ep. 26 of Podocyte Talk: – Finerenone + empagliflozin: better together in DKD – Hypoglycaemia common post-dialysis in older adults – Tirzepatide lowers albuminuria in obesity, with/without diabetes Listen now! #CKD #Nephrology #Diabetes #GLP1 youtu.be/NiNvQYVdhIw

Dual therapy with finerenone + empagliflozin cut albuminuria by ~30% more than either drug alone in CKD + T2D—with no added safety concerns. A promising step for combo treatment in DKD. #CKD #T2D #SGLT2i #Finerenone #CONFIDENCE #Nephrology #BlueskyMD

Episode 25 of Podocyte Talk is out! 🎧 Albuminuria predicts AF in the elderly 💉 Rituximab shows >95% 10-yr renal survival in MN 🫁 Pre-KTx pulmonary HTN = higher graft loss Smart nephrology insights you can use. #CKD #Nephrology #Podcasts youtu.be/EO0eLgu6uuw

Podocyte Talk Episode 24: – SGLT2i vs GLP-1RA in real-world CKD care – Finerenone works regardless of early eGFR drop – High-carb diets raise mortality in dialysis patients #Nephrology #KidneyCare #Finerenone #SGLT2i #GLP1RA #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/uMbtbhPYBPc

Simultaneous initiation of SGLT2i, RASi, ns-MRA, and GLP1-RAs presents a promising approach to mitigate the risk of CV events and the progression of kidney disease in patients with CKD. #podocytetalk #Nephpearls #Nephrology #CKD journals.lww.com/jasn/abstrac...

Finerenone reduced kidney and cardiovascular events in CKD and T2D patients, regardless of frailty. Benefits included lower albuminuria and slower eGFR decline, supporting its use even in frail individuals. #podocytetalk #Nephpearls #Nephrology #CKD journals.lww.com/cjasn/abstra...

Patients receiving SGLT2i demonstrated lower rates of progression to KRT compared to those receiving GLP1RA. These findings may inform the choice of these therapies in the setting of CKD and T2DM. #podocytetalk #Nephpearls #Nephrology #CKD #nephsky www.ajkd.org/article/S027...

In patients with CKD and T2DM, finerenone reduced cardiovascular and kidney events regardless of whether eGFR rose or declined in the first month. Even with >10% acute eGFR drop, benefits were preserved. #podocytetalk #CKD #Nephsky www.kidney-international.org/article/S008...

In a diverse IgAN cohort, 36% reached kidney failure, major eGFR decline, or died within 2.7 years. Proteinuria ≥0.5 g/g strongly predicted poor outcomes, challenging past beliefs that <1 g/g is low risk. #podocytetalk #Nephpearls #Nephrology #CKD #nephsky academic.oup.com/ndt/advance-...

Kidney outcomes were poor in genetic nephrotic syndrome; in FSGS outcomes were strongly associated with proteinuria level. MCD patients had better proteinuria control than FSGS and had better outcomes at each proteinuria level. #podocytetalk #Nephpearls #nephsky journals.lww.com/jasn/abstrac...

In IgA nephropathy, dapagliflozin slowed eGFR decline, especially in patients with faster pre-treatment loss. The pre-treatment eGFR slope predicted post-treatment benefit, suggesting value in guiding therapy. #podocytetalk #CKD #GN #Nephsky www.kireports.org/article/S246...

In CKD, furosemide use—especially >100 mg/day—is linked to higher serum levels of protein-bound uraemic toxins like IS, PCS, Kyn, and IAA. Furosemide may impair toxin clearance via OAT1/3 transporters, contributing to toxin accumulation. #podoctyetalk #CKD #Nephsky www.kireports.org/article/S246...

In Episode 23 of Podocyte Talk, we dive into three important new studies: use of finerenone in IgA nephropathy, incidence and outcomes of acute kidney injury in very old patients, and risk of UTIs with SGLT2 inhibitors #podocytetalk #Nephpearls #Nephrology #CKD #nephsky youtu.be/X5dh2G-FAuI

Podocyte Talk is now twice monthly! Each episode includes 2 multiple-choice questions—answer in the comments and test your nephrology knowledge! In this episode, we explore three impactful studies in nephrology #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/C1MQgOdVdv4

✅ SGLT2 inhibitors in patients with advanced CKD ✅ Anti-nephrin antibodies as relapse predictors in MCD & FSGS ✅ Sacubitril/valsartan improves dialysis access flow in heart failure #podocytetalk #Nephpearls #Nephrology #CKD #nephsky youtu.be/YkNoV6CDmxU

Among low-risk patients undergoing PCI, contrast-associated AKI was rare, and withholding or continuing SGLT2 inhibitors had no impact on AKI risk or renal function. discontinuation in this setting may not be necessary. journals.lww.com/kidney360/pa... #Podocytetalk @asnpublications.bsky.social

This study highlights the negative impact of hypertension early after kidney transplantation and emphasizes the importance of effective treatment to improve long-term graft and patient survival. www.kireports.org/article/S246... #Podocytetalk #nephrology #CKD #Nephsky

BP targets post kidney transplant, SGLT2i use in angiography, and CGM insights in dialysis—all in Ep. 20 of Podocyte Talk. Tune in for key updates in nephrology! 🎧 #Nephrology #KidneyCare #podocytetalk #Nephpearls #nephsky youtu.be/fW2Ug1Sk9Rk

This week, we break down three major nephrology studies: ✅ Obinutuzumab’s role in lupus nephritis ✅ Best phosphate binders for dialysis patients ✅ Long-term effects of tolvaptan in ADPKD #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/86pdnfUKlsA

A JASN study links higher CKM stages to increased 15-year CV mortality (Stage 0: 5.5%, Stage 4: 15.2%). Stage 4 had a 9.6% higher risk. Early intervention is crucial. journals.lww.com/jasn/pages/a... #Podocytetalk #Nephrology #CKM

Tolvaptan slowed kidney function decline by 14%, reducing eGFR loss over time. However, it did not significantly impact total kidney volume (TKV) growth. Patients with higher osmolar intake showed a greater treatment response #Podocytetalk #nephsky #nephrology academic.oup.com/ndt/advance-...

In this episode of Podocyte Talk, we explore the impact of obesity on polycystic kidney disease progression, the predictive power of albuminuria in IgA nephropathy, and how tacrolimus metabolism affects kidney transplant outcomes #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/cFq0B8kr_ZU

In patients with HRS-1 who are adequately treated with norepinephrine and achieved an optimal MAP increment, addition of i.v. furosemide enhances diuresis without negatively affecting renal recovery. www.kireports.org/article/S246... #podocytetalk #Nephpearls #Nephrology #CKD #nephsky

High-intensity interval training significantly reduced the risk of rapid eGFR decline in older adults. journals.lww.com/jasn/abstrac... #podocytetalk #Nephpearls #CKD #nephsky

Can exercise slow kidney decline? How does Cardiovascular-Kidney-Metabolic (CKM) syndrome impact long-term survival? And can diuretics be safely used in hepatorenal syndrome? #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/2MgEtM6sh1w

Key Breakthroughs in Kidney Disease & Transplantation "Exploring new insights into IgA nephropathy, kidney transplantation in lupus nephritis, and thrombotic microangiopathy post-transplant." #podocytetalk #Nephpearls #Nephrology #CKD #nephsky youtu.be/huUGTkIet04

No association was observed between aspirin use and risk of nonfatal atherosclerotic CVD or cardiovascular death in patients with CKD stages G3 and G4 without prior CVD. Aspirin use was associated with higher risk of major bleeding. journals.lww.com/cjasn/abstra... #podocytetalk #CKD #nephsky

In people with non–dialysis-dependent CKD, revascularization may be associated with lower all-cause mortality compared with medical management and may also lower the risk of cardiovascular events. journals.lww.com/cjasn/pages/... #podocytetalk #Nephpearls #CKD #nephsky

These findings support the use of sodium-glucose cotransporter-2 inhibitors in CKD, irrespective of frailty, multimorbidity, or polypharmacy. CJASN 19(9):p 1119-1129, September 2024 #podocytetalk #Nephpearls #CKD #nephsky journals.lww.com/cjasn/fullte...

Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy #podocytetalk #Nephpearls #CKD #nephsky www.kireports.org/article/S246...

The presence of anti-PLA2R1 antibodies prior to transplantation was a strong predictor of recurrence of allograft membranous nephropathy. #podocytetalk #Nephpearls #CKD #nephsky www.kireports.org/article/S246...

In this episode, we cover three key studies: ✅ Iron therapy reduces heart failure risk in CKD. ✅ Empagliflozin benefits frail CKD patients. ✅ Long-term outcomes of pancreas-kidney transplants. #podocytetalk #Nephrology #CKD #nephsky youtu.be/WIeE035sYtQ

In patients with CKD included in this MINT subgroup analysis, a liberal transfusion strategy was not worse than a restrictive transfusion strategy and was associated with less harm in subgroups not receiving dialysis. journals.lww.com/jasn/abstrac... #podocytetalk #Nephpearls #CKD

Greater attention should be given to RV and LA dysfunction for early identification of cardiac dysfunction in CKD patients. Nephrology Dialysis Transplantation 04 October 2024 doi.org/10.1093/ndt/... #podocytetalk #Nephpearls #CKD #nephsky

HDF potentially improves VA patency rates compared with HD, even in patients with cardiovascular disease or diabetes, commonly associated with poor patency. Nephrology Dialysis Transplantation, 24 January 2025 doi.org/10.1093/ndt/... #podocytetalk #Nephpearls #CKD #nephsky

LYFT updated for older kidney transplant candidates; transplant still better than dialysis (5-year LYFT). Trends slightly declined; needs nuanced metrics for policy. #podocytetalk #Nephpearls #CKD #nephsky

Benefits of haemodiafiltration for vascular access patency, liberal blood transfusion strategies for MI in advanced CKD, and impact of pruritus in dialysis patients with management insights. Tune in for these essential updates! #podocytetalk #Nephpearls #Nephrology #CKD youtu.be/SvCnUG9J1Ww

1️⃣ role of hyperkalemia in chronic kidney disease progression and mortality. 2️⃣ impact of glomerular hyperfiltration on cardiovascular disease risks in T2DM. 3️⃣ safety concerns of ondansetron in hemodialysis patients. #podocytetalk #Nephpearls #Nephrology #CKD #nephsky youtu.be/T1o4H4BqfIg

Vadadustat once daily, but not three times weekly, was noninferior to DA in the correction and maintenance of hemoglobin in patients with dialysis-dependent CKD converted from an ESA. Kidney360 5(11):p 1652-1661, November 2024. | DOI: 10.34067/KID.0000000567 #podocytetalk #nephsky #nephrology

Compared with initiation of antiemetics with lesser QT-prolonging potential, initiation of ondansetron was associated with higher short-term cardiac risks among people receiving hemodialysis. JASN 35(6):p 761-771, June 2024. | DOI: 10.1681/ASN.0000000000000336 #podocytetalk #nephsky #nephrology

Restarting RASi after discontinuation was associated with a lower risk of kidney outcomes and mortality but not related to the incidence of hyperkalemia. Journal of the American Society of Nephrology 35(10):p 1391-1401, October 2024. | DOI: 10.1681/ASN.0000000000000425 #podocytetalk #nephsky

SGLT2 inhibitors (SGLT2i) consistently reduce kidney outcomes across the spectrum of KDIGO classes and UACR levels in individuals with type 2 diabetes (T2D), CKD, & heart failure. Clin J Am Soc Nephrol. 2025 Jan 1;20(1):39-49. doi: 10.2215/CJN.0000000000000568. #podocytetalk #nephsky #nephrology

SGLT2 inhibitor and GLP-1 RA discontinuation was common and associated with harmful outcomes in adults with CKD. Journal of the American Society of Nephrology 36(1):p 87-98, January 2025. | DOI: 10.1681/ASN.0000000000000477 #podocytetalk #Nephpearls #Nephrology #CKD